1Wakabayashi K,Tanji K,Mori F,et al. The Lewy body in Parkinson's disease:molecules implicated in the formation and degradation of alpha-synuclein aggregates [ J ]. Neuropathology, 2007,27 ( 5 ) : 494 - 506
2Collier T J, Lipton J, Daley BF, et al. Aging-Related Changes in the Nigrostriatal Dopamine System and the Response to MPTP in Non-human Primates: Diminished Compensatory Mechanisms as a Prelude to Parkinsonism[ J ]. Neurobiol Dis, 2007,26 ( 1 ) : 56 - 65
3Clarke G, Lumsden CJ, Mclnnes RR. Inherited neurodegenerative diseases: the one-hit model of neurodegeneration [ J ]. Hum Mol Genet,2001,10(20) :2269 - 2275
4Di Monte DA,Lavasani M, Manning-Bog AB. Environmental factors in Parkinson' s disease [ J ]. Neurotoxieology, 2002,23 ( 4/5 ) : 487-502
5Lee FJ,Liu F,Pristupa ZB,et al. Direct binding and functional coupling of alpha-synuelein to the dopamine transporters accelerate dopamine-indueed apoptosis[ J ]. FASEB J ,2001,15(6) :916- 926
6Prediger RD,Batista LC, Medeiros R,et al. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Experimental[J]. Neurology,2006, 202(2) :391 - 403
7Rojo AI, Montero C, Salazar M, et al. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice [J]. Eur J Neurosci,2006,24(7) :1874- 1884
8Bradbury A J, Costall B, Domeney AM, et al. 1 - methyl - 4 - phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway [J]. Nature,1986,319(6048):56-57
9Manning-Bo AB, Caudle WM, Perez XA, et al. Increased vulnerability of nigrostriatal terminals in DJ - 1 - deficient mice is mediated by the dopamine transporter[J]. Neurobiol Dis,2007,27(2) :141 -50
10Ossowska K, Wardas J, Kuter K, et al. Influence of paraquat on dopaminergic transporter in the rat brain [ J ]. Pharmaeo Rep, 2005,57(3) :330 - 335
